Apparent Treatment-Resistant Hypertension in the First Year Associated with CV Mortality in PD Patients

Qingyao Zhu,Zhihao Huo,Fang Zeng,Nirong Gong,Peiyi Ye,Jianyi Pan,Yaozhong Kong,Xianrui Dou,Di Wang,Shuting Huang,Cong Yang,Dehui Liu,Guangqing Zhang,Jun Ai

DOI: https://doi.org/10.1093/ajh/hpae010

2024-01-22

American Journal of Hypertension

Abstract:Abstract Background Few reports have focused on the association between apparent treatment-resistant hypertension (aTRH) and cardiovascular (CV) mortality in peritoneal dialysis (PD) population, thus we conducted this retrospective cohort to explore it. Patients and Methods: This was a retrospective cohort study conducted from January 2011 to January 2020 with PD patients in 4 Chinese dialysis centers. ATRH was defined according to the American College of Cardiology and American Heart Association guidelines. ATRH duration was calculated as the total number of months when patients met the diagnostic criteria in the first PD year. The primary outcome was CV mortality, and the secondary outcomes were CV events, all-cause mortality, combined endpoint (all-cause mortality and transferred to HD), and PD withdrawal (all-cause mortality, transferred to HD and kidney transplantation). Cox proportional hazards models were used to assess the association. Results A total of 1,422 patients were finally included in the analysis. During a median follow-up period of 26 months, 83 (5.8%) PD patients incurred CV mortality. The prevalence of aTRH was 24.1%, 19.9%, 24.6% at 0, 3, 12 months after PD initiation respectively. Overall, aTRH duration in the first PD year positively associated with CV mortality (per 3 months increment, adjusted HR, 1.29; 95% CI 1.10, 1.53; P=0.002). After categorized, those with aTRH duration more than 6 months presented the highest adjusted HR of 2.92. Similar results were found for secondary outcomes, except for the CV event. Conclusion Longer aTRH duration in the first PD year is associated with higher CV mortality and worse long-term clinical outcomes. Larger studies are warranted to confirm these findings.

peripheral vascular disease

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: the association between apparent treatment - resistant hypertension (aTRH) and cardiovascular (CV) mortality in peritoneal dialysis (PD) patients. Specifically, through a retrospective cohort study, the researchers explored the relationship between the duration of aTRH and subsequent cardiovascular mortality and other long - term clinical outcomes in peritoneal dialysis patients. The research background indicates that although significant progress has been made in hypertension management techniques, blood pressure control in peritoneal dialysis patients still poses a great challenge, and approximately 48% - 77% of PD patients have poor blood pressure control. Therefore, understanding the prevalence of aTRH in PD patients and its impact on long - term clinical outcomes is of great significance for improving the prognosis of these patients.

The main findings of the study include:
- The incidence of aTRH in PD patients was 24.1%, 19.9% at 3 months, and 24.6% at 12 months.
- The duration of aTRH was positively correlated with cardiovascular mortality. For every additional 3 months, the adjusted hazard ratio (HR) was 1.29 (95% CI 1.10, 1.53; P = 0.002).
- For aTRH patients with a duration of more than 6 months, the adjusted HR was the highest, reaching 2.92.
- Similar results were also observed in all - cause mortality, combined endpoint events (all - cause mortality and conversion to hemodialysis), and PD withdrawal (all - cause mortality, conversion to hemodialysis, and kidney transplantation), but there was no statistical significance for cardiovascular events.

In conclusion, this study emphasizes the importance of early continuous blood pressure monitoring in PD patients and suggests that further research is needed to confirm the causal relationship between aTRH and clinical outcomes.